The FDA approves the Novavax coverage vaccine after delay

Helen Branswell covers questions largely linked to infectious diseases, including epidemics, preparation, research and the development of vaccines. Follow it on Mastodon and Bluesky. You can reach Helen on signal at Hbranswell.01.

The Food and Drug Administration finally approved the COVVI-19 Novavax vaccine, but in doing so, this imposed restrictions on its two competitors on the American market is not confronted.

The long -awaited license limits the use of the vaccine to people aged 65 and over and people aged 12 to 64 who have at least one medical condition which presents them at a higher risk of serious illness if they contract cocovid. The vaccine is available under an emergency use authorization.

The FDA has missed a deadline of April 1 to reign on the request for Novavax. It was reported that the appointments of the commissioner Marty Makary’s office replaced the career staff, who recommended issuing the license. Novavax’s equity rate has been down 21% since the start of the year.